AWHL (Aspira Womens Health) Growth Rank: 7 (As of Sep. 17, 2026) — 17% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AWHL Aspira Womens Health Inc AWHL
35 GF Score
Price $0.29
GF Value $0.26
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Aspira Womens Health Growth Rank?

Aspira Womens Health AWHL -1.20% 35 Growth Rank is 7 as of Sep. 17, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates AWHL with a GF Score™ of 35/100 and a GF Value™ of $0.26 (Fairly Valued). The stock has 8 warning signs investors should review.

Aspira Womens Health has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Aspira Womens Health Growth Rank Related Terms

AWHL vs MBAI, XWEL, ADVB: Growth Rank Comparison

For the Diagnostics & Research subindustry, Aspira Womens Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Growth Rank falls into.


AWHL
35GF Score
Aspira Womens Health Inc AWHL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Aspira Womens Health (AWHL) has a Growth Rank of 7 as of Sep. 17, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Aspira Womens Health and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Aspira Womens Health's Growth Rank has ranged from 1.00 to 9.00.
Is Aspira Womens Health's Growth Rank too high?
Aspira Womens Health's current Growth Rank of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Aspira Womens Health has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Growth Rank compare to MBAI and XWEL?
Aspira Womens Health's Growth Rank of 7 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Aspira Womens Health's own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current Growth Rank is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Fairly Valued. The stock's GF Value™ is $0.26, compared to a current price of $0.29 — trading 10.2% above its estimated fair value. The current Growth Rank is 7, which is 17% above median its 10-year median of 6.00. Aspira Womens Health's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Growth Rank is 7 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.29 is trading 10.2% above its estimated GF Value™ of $0.26. GuruFocus considers Aspira Womens Health to be Fairly Valued.

Key valuation signals for AWHL:

  • Growth Rank: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: $0.26 vs. price of $0.29 (10.2% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
35GF Score

Get the complete analysis for AWHL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$0.26
GF Value